Lantheus Halts 2026 Guidance as $8B Curium Deal Takes Over

Forward-Looking Analysis

Lantheus Holdings will not provide fiscal year 2026 guidance due to the pending merger with Curium. Consequently, specific projected revenue, net income, and EPS estimates for 2026Q2 are unavailable as the company has suspended its previously issued guidance. No analyst upgrades, downgrades, or price target revisions were included in the provided source material. The financial focus has shifted entirely to the merger terms rather than standalone quarterly performance metrics.

Historical Performance Review

Lantheus Holdings reported strong 2026Q1 results, generating $377.33 million in revenue and $118.42 million in net income. Earnings per share reached $1.83, supported by a robust gross profit of $230.92 million. These figures reflect solid operational execution prior to the strategic transaction announcement, demonstrating the company's consistent ability to drive top-line growth and maintain healthy margins in the radiopharmaceutical sector.

Additional News

Curium announced a definitive agreement to acquire Lantheus in a transaction valued at up to $8.0 billion. Lantheus shareholders will receive $102.50 per share in cash at closing, plus up to $12.00 per share in Contingent Value Rights (CVRs) tied to commercial milestones through 2030. The total consideration of up to $114.50 per share represents a 38% premium to Lantheus’ 60-day VWAP. The merger combines Curium’s global theranostics platform with Lantheus’ U.S. radiodiagnostics business, creating a entity serving over 70 countries. Lantheus’ Board unanimously approved the deal. The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals. Lantheus will operate independently until closing and will cease to be publicly traded upon completion. No earnings conference call will be hosted for the second quarter due to the pending transaction.

Summary & Outlook

Lantheus demonstrates strong financial health, evidenced by Q1’s $118.42 million net income and $1.83 EPS. The primary catalyst is the $8.0 billion acquisition by Curium, offering immediate value via $102.50/share cash plus potential upside. However, growth visibility is temporarily obscured as guidance is suspended and the company operates as a target. The outlook is neutral for independent equity appreciation, as the stock price is anchored near the acquisition offer. While the deal validates long-term strategic value, near-term trading is driven by merger arbitrage rather than operational growth, limiting upside potential amidst deal completion risks.